Abbreviations: ASCT = autologous stem cell transplant; CR = complete response; IMiDs = immunomodulators; IMWG = International Myeloma Working Group; ORR = overall response rate; PI = proteasome inhibitors; PD = progressive disease; PR = partial response; VGPR = very good partial response; SCT = stem cell transplant. Best IMWG response was available for only 580 patients undergoing first line salvage therapy and 425 patients undergoing second line salvage therapy.
Autologous stem cell transplant (ASCT) remains an integral part of the treatment of eligible patients with multiple myeloma (MM). It is usually performed either in the upfront setting as consolidation after induction therapy or in a delayed fashion for management of relapsed disease. Unfortunately, disease relapse or progression of disease post ASCT remain inevitable for most patients irrespective of the timing of the ASCT. 1, 2 However, the clinical features at the time of relapse and subsequent clinical outcomes are quite heterogeneous amongst these patients. This information is particularly important given that it may provide new benchmarks when comparing different therapies in the post-ASCT relapse setting in clinical trials. It can also identify subsets of patients who are at the risk of having poor outcomes upon relapse post ASCT in order to study the utility of treating them with more intensive or novel therapies. This study describes the natural history of the disease and survival outcomes at the time of relapse or disease progression in patients with MM who received an ASCT as part of their treatment either in the upfront or delayed setting.
A total of 672 MM patients who had undergone an ASCT had experienced a documented relapse or disease progression between 1 January 2000 and 31 December 2012. Of these patients, 468 (70%) underwent an upfront ASCT defined as an ASCT within 1 year from the diagnosis of MM, whereas the remaining 204 patients had a delayed ASCT which was defined as an ASCT performed at least 1 year or more from the diagnosis of MM. The median estimated follow-up for this entire cohort from diagnosis was 149 months (95% CI: 135-159) and from first relapse post ASCT was 94 months (95% CI: 84-106). 
The median (range) age at ASCT was 60 years (29-75). Of the 366 patients who had FISH testing results available, 104 (28%) were categorized as high risk based on the presence of either t(4;14), t(14;16), t(14;20) or deletion 17p. All patients received novel agent therapies such as proteasome inhibitors (PIs) and/or immunomodulators (IMiDs) during their disease course with 59% receiving them during their induction phase upon diagnosis. There were 88 (13%) patients who received some form of maintenance therapy after their day 100 evaluation. However, only 50 of these patients received maintenance therapy consisting of either IMiDs or PIs. The median number of regimens prior to ASCT and post-ASCT relapse were 1 (range: 0-3) and 3 (range: 0-13), respectively. The median total number of regimens documented to have been received by patients included in this study cohort was 5 (range: 3-19).
The median time to relapse post ASCT in this cohort of patients was 18 months (range: 2-184) and 13 months (range: 2-107) in the upfront and delayed ASCT groups, respectively. Most patients, 118 (67%) in the upfront ASCT group and 353 (71%) in the delayed ASCT group had serologic-only relapses. Patients with symptomatic relapses had a higher PCLI (P = 0.024) and were more likely to present with International Staging System (ISS) stage 3 disease (P = 0.021) at diagnosis. The spectrum of salvage therapies used in 1st and 2nd line settings upon ASCT relapse and the distributions of their best IMWG-based response 3 are described in Table 1 . IMiD-and PI-based regimens were the two most common first and second line salvage therapies utilized in this patient cohort. There were 127 (19%) patients who underwent a second ASCT and 23 (3%) underwent an allogeneic stem cell transplant as salvage therapy at some point in their disease course.
After patients relapsed post ASCT in the upfront ASCT group and were then treated with a first line salvage therapy, the median time to next therapy (TTNT), which is defined as the time taken to switch to the second line of salvage therapy was 19 months in those patients who achieved a response of at least a VGPR or better (N = 107) to the first line salvage therapy compared with 5 months in patients who achieved a response of less than a VGPR (N = 289) (Po 0.001). Similarly, among patients who underwent a delayed ASCT, the median TTNT was 15 months in those patients who achieved a response of at least a VGPR or better (N = 35) compared with 4 months in patients who achieved a response of less than a VGPR (N = 141) (P o 0.001). The median (95% CI) overall survival after progression post stem cell transplant (Prog-OS) which is defined as the survival post ASCT relapse was 39 (33-43) and 27 (22-34) months for patients receiving an upfront and delayed ASCT, respectively. The median Prog-OS was 60 months in those patients who relapsed at least 24 months post ASCT (N = 145) compared with 29 months in patients relapsing prior to 24 months (N = 323) (P o 0.001) for the upfront ASCT group (Figure 1a) . The median Prog-OS was longer in those patients who relapsed after 24 months (N = 32) compared with those relapsing before 24 months (N = 172) (66 vs 23 months; P o 0.001) for the delayed ASCT group (Figure 1b) . When the patients were grouped based on undergoing ASCT before first disease relapse (N = 460) compared with ASCT after at least one relapse (N = 212), the median Prog-OS was 41 months vs 23 months (P o 0.001).
Shorter time to relapse, presence of hypercalcemia, renal insufficiency, anemia and lytic bone lesions (CRAB) symptoms or extramedullary disease at relapse, high plasma cell labeling index (PCLI) at diagnosis (⩾2%), more number of therapies prior to ASCT and not achieving at least a VGPR to the first salvage therapy were all associated with a shorter Prog-OS in patients irrespective of whether they underwent an upfront or a delayed ASCT. High-risk FISH and ISS 3 stage at diagnosis were not predictive of a worse Prog-OS in either upfront or delayed ASCT.
All patients upon relapse post ASCT tend to get labeled as having 'relapsed disease', which in turn reflects a grim prognosis. 4 However, the clinical outcomes amongst such patients are quite heterogeneous and very few studies have documented their clinical course and subsequent therapies received. [5] [6] [7] We specifically analyzed the Prog-OS for patients undergoing early or delayed ASCT separately. This was because patients undergoing a delayed ASCT would have relapsed with more chemotherapy exposure and thus more likely to have a more aggressive disease course upon relapse. Nevertheless, our study demonstrates that the median Prog-OS is more than twice as long as the median time to progression after ASCT. Even though the median time to relapse post ASCT in this study cohort appears to be short (that is, 18 months for the upfront ASCT group and 13 months for the delayed ASCT group), this is likely because this study evaluates only patients who relapsed post ASCT and is not taking into consideration the patients who did not relapse as of yet.
The types of first and second line salvage therapies received were quite variable and likely reflect the time period of relapse and physician preference. Nevertheless, achieving a deep response to therapy (that is, first line salvage therapy) such as a VGPR or better was not uncommon and was significantly associated with an improved Prog-OS in both the upfront and delayed ASCT cohorts. The prognostication value of depth of response is intricately tied to tumor sensitivity to therapy. However, due to variable forms of salvage treatments (that is, doublet vs triplet therapy or IMiD vs PI vs IMiD/PI combination and so on) leading to small numbers of patients in each group, comparisons between the various therapies were not possible. A second ASCT has been shown to be a valuable therapeutic option for patients with MM who relapse after already undergoing an initial ASCT. 8, 9 Similarly, the response rates of a second ASCT as first or second line salvage therapy in this study was in the range of 88-96% (Table 1) . Furthermore, recent trial data demonstrate improved progression-free survival and depth of response with the use of combination novel therapies such as ASPIRE, 10 ELOQUENT, 11 MMVAR/IFM 2005-04 (ref.12 ) and so on in patients with relapsed disease.
Given the limitations of the single center retrospective nature of this study, heterogeneous mix of patients included in this cohort and non-uniformity of salvage therapies prescribed, we are unable to generalize the findings in this study to all patients with MM who relapse post ASCT. Secondly, recent data from the IFM study 13 and the CALGB 14 demonstrate improved progression free survival (PFS) in both studies and OS benefit only in the latter study with the use of post-ASCT maintenance; however most patients in this study did not receive maintenance therapy, as the cohort was from a time period prior to the mainstream adoption of maintenance therapy and hence may not reflect current practices post ASCT. Finally, data regarding the influence of minimal residual disease 15 or even achievement of stringent complete response 2 were unavailable for most patients in this large cohort and hence were not included in this study. Nevertheless, this study identified various prognostic factors affecting Prog-OS and demonstrates that a subset of patients with MM can fare well despite experiencing post-ASCT relapse or disease progression. Furthermore, it confirms that deep responses to various chemotherapy regimens are attainable in patients with post-ASCT-relapsed disease and correlate with improved Prog-OS outcomes.
